Checkpoint Therapeutics' (CKPT) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT - Free Report) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock traded down $0.28 on Monday, reaching $3.39. The company's stock had a trading volume of 16,494,230 shares, compared to its average volume of 624,046. Checkpoint Therapeutics has a twelve month low of $1.36 and a twelve month high of $4.50. The company has a market cap of $165.53 million, a price-to-earnings ratio of -1.83 and a beta of 1.34. The business's fifty day moving average price is $3.48 and its 200 day moving average price is $2.66.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). As a group, equities analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CKPT. Vanguard Group Inc. increased its stake in shares of Checkpoint Therapeutics by 67.4% in the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company's stock valued at $1,882,000 after buying an additional 369,586 shares during the period. B. Riley Wealth Advisors Inc. increased its position in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company's stock worth $493,000 after purchasing an additional 180,050 shares during the period. PVG Asset Management Corp bought a new stake in Checkpoint Therapeutics during the 2nd quarter worth about $295,000. Geode Capital Management LLC lifted its position in Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company's stock valued at $958,000 after purchasing an additional 124,787 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company's stock valued at $291,000 after purchasing an additional 80,000 shares during the last quarter. Institutional investors own 22.00% of the company's stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.